Madurai, October 8, 2026: Thyrocare Technologies Limited has launched a new diagnostic laboratory in Madurai, Tamil Nadu, as part of its ongoing expansion to improve access to affordable and quality diagnostic services across the region. The facility was inaugurated by Rahul Guha, Managing Director and CEO of Thyrocare and API Holdings.
The new laboratory is equipped to handle both routine and specialised diagnostic testing, supported by trained professionals and technology-enabled processes. Thyrocare stated that the facility will cater to patients, laboratories, and healthcare partners in Madurai and neighbouring areas, aiming to meet the growing healthcare needs of the region.
Focus on emerging markets
Thyrocare said the Madurai laboratory strengthens its local presence in Tamil Nadu and aligns with its strategy to expand beyond metropolitan markets. The company emphasised the importance of standardised processes, timely sample processing, and reliable reporting in delivering diagnostic services closer to patients.
Leadership comments on expansion
“At Thyrocare, our focus has always been on making quality and trustworthy diagnostic services more accessible to people across India. The launch of our new laboratory in Madurai is another step towards strengthening our presence in emerging markets and bringing our technology-led diagnostic capabilities closer to patients,” said Rahul Guha, Managing Director and CEO, Thyrocare and API Holdings.
Dr Ramesh Kinha, Chief Operating Officer, Thyrocare, said the new facility will support a comprehensive range of routine and specialised testing, backed by the company’s standardised processes, technology, and quality protocols. He added that the laboratory is an important part of Thyrocare’s efforts to expand access to quality diagnostics across Tamil Nadu and the southern region.
National network and accreditations
Thyrocare reported that it has achieved 100% NABL accreditation across all its laboratories. The company operates a network of laboratories across India, with a quarterly active franchise count of over 10,000 and more than 53.3 million diagnostic and screening investigations processed in Q2FY26. Thyrocare holds ISO 9001:2015, NABL, and College of American Pathologists (CAP) accreditations.
Thyrocare Technologies Limited (NSE: THYROCARE, BSE: 539871) is a diagnostics company with a national presence, providing services to laboratories and hospitals across India.
Disclaimer: This article is based on a press release provided by the concerned organisation and has been edited for style and clarity with the assistance of AI tools. BusinessFortnight does not verify, endorse, or take responsibility for the claims, figures, or statements made in the original release.
